- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 37/02 - Immunomodulators
Patent holdings for IPC class A61P 37/02
Total number of patents in this class: 4897
10-year publication summary
176
|
192
|
182
|
281
|
417
|
390
|
538
|
529
|
486
|
141
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2961 |
49 |
Daiichi Sankyo Company, Limited | 1829 |
38 |
The Regents of the University of California | 18943 |
33 |
Bristol-myers Squibb Company | 5080 |
29 |
Ono Pharmaceutical Co., Ltd. | 454 |
28 |
The University of Tokyo | 3903 |
27 |
Dainippon Sumitomo Pharma Co., Ltd. | 234 |
26 |
Taisho Pharmaceutical Co., Ltd. | 844 |
26 |
Mitsubishi Tanabe Pharma Corporation | 579 |
23 |
Osaka University | 3143 |
23 |
Shanghai Hengrui Pharmaceutical Co., Ltd. | 588 |
23 |
Chugai Seiyaku Kabushiki Kaisha | 1259 |
22 |
Regeneron Pharmaceuticals, Inc. | 3650 |
22 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
22 |
The Trustees of the University of Pennsylvania | 4122 |
21 |
Novartis AG | 11238 |
20 |
Jiangsu Hengrui Medicine Co., Ltd. | 780 |
20 |
F. Hoffmann-La Roche AG | 7958 |
19 |
ChemoCentryx, Inc. | 400 |
18 |
AstraZeneca AB | 3042 |
17 |
Other owners | 4391 |